HD reaches more brain structures than we thought: new research broadens our understanding of the earliest signs of HD
A confusing story about a huntingtin lowering trial is published in the Telegraph, but cool new stuff is happening!
Stem cells and modeling Huntington's disease in our final Therapeutics Conference report
Strategies for getting rid of mutant huntingtin & clinical trial updates: day 2 of the HD therapeutics conference
The news has recently been full of stories about CRISPR, a new "jaw-dropping" DNA-editing technology. Hype or hope?
Proteins and DNA - Jeff and Ed report from day 1 of the 2016 #huntingtonsdisease therapeutics conference
Researchers design a virus to more effectively deliver gene-silencing drugs throughout the brain.
Sleep deficits precede motor problems in HD
Phase 2/3 clinical trial results prove inconclusive for Huntington's drug cysteamine.
An existing drug could give a boost to HD brain cells – but it may need more testing before it’s back in the clinic
Companions of HD gene carriers are more likely to notice psychological changes in presymptomatic HD.